Cargando…

Management of hyperphosphataemia in chronic kidney disease—challenges and solutions

Hyperphosphataemia is a clinical consequence of the advanced stages of chronic kidney disease (CKD). Considerable evidence points to a role of hyperphosphataemia in the pathogenesis of CKD-associated cardiovascular (CV) complications, including vascular calcification, and with increased all-cause an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ketteler, Markus, Wüthrich, Rudolf P., Floege, Jürgen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2013
Materias:	Original Contributions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4432434/ https://www.ncbi.nlm.nih.gov/pubmed/26019840 http://dx.doi.org/10.1093/ckj/sfs173

Ejemplares similares

Plant-based dietary approach to stage 3 chronic kidney disease with hyperphosphataemia
por: Campbell, Thomas M, et al.
Publicado: (2019)

Real-world management of hyperphosphataemia with sucroferric oxyhydroxide: the VELREAL multicentre study
por: Navarro-González, Juan F, et al.
Publicado: (2021)

Growth of arachnoid cysts in patients with autosomal dominant polycystic kidney disease: serial imaging and clinical relevance
por: Krauer, Fabienne, et al.
Publicado: (2012)

Tailored synbiotic powder (functional food) to prevent hyperphosphataemia (kidney disorder)
por: Anand, Ajeeta, et al.
Publicado: (2021)

Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease–mineral bone disorder parameters in dialysis patients
por: Ketteler, Markus, et al.
Publicado: (2019)

Modified-release nicotinamide for the treatment of hyperphosphataemia in haemodialysis patients: 52-week efficacy and safety results of the phase 3 randomized controlled NOPHOS trial
por: Ketteler, Markus, et al.
Publicado: (2022)

Real-world safety and effectiveness of sucroferric oxyhydroxide for treatment of hyperphosphataemia in dialysis patients: a prospective observational study
por: Vervloet, Marc G, et al.
Publicado: (2021)

Where are we now? Emerging opportunities and challenges in the management of secondary hyperparathyroidism in patients with non-dialysis chronic kidney disease
por: Ketteler, Markus, et al.
Publicado: (2021)

Author Correction: Tailored synbiotic powder (functional food) to prevent hyperphosphataemia (kidney disorder)
por: Anand, Ajeeta, et al.
Publicado: (2021)

Potential Future Uses of Calcimimetics in Patients with Chronic Kidney Disease
por: Chonchol, Michel, et al.
Publicado: (2008)

Axl Tyrosine Kinase Protects against Tubulo-Interstitial Apoptosis and Progression of Renal Failure in a Murine Model of Chronic Kidney Disease and Hyperphosphataemia
por: Hyde, Gareth D., et al.
Publicado: (2014)

Symptomatic Hyperphosphataemia Following Phosphate Enema in A Healthy Adult
por: Carl, Ian, et al.
Publicado: (2007)

Considerations about the effectiveness and cost effectiveness of therapies in the treatment of hyperphosphataemia
por: Plagemann, Thomas, et al.
Publicado: (2011)

Investigation of the transforming growth factor-beta 1 signalling pathway as a possible link between hyperphosphataemia and renal fibrosis in feline chronic kidney disease
por: Lawson, J.S., et al.
Publicado: (2021)

Severe hypocalcaemia and hyperphosphataemia caused by oral sodium phosphate fleet solution in a haemodialysis patient after parathyroidectomy
por: Mok, Maggie Ming Yee, et al.
Publicado: (2011)

Cardiac Remodeling in Chronic Kidney Disease
por: Kaesler, Nadine, et al.
Publicado: (2020)

Anticoagulation in chronic kidney disease patients—the practical aspects
por: Hughes, Stephen, et al.
Publicado: (2014)

Association of Arterial Stiffness With Kidney Function Among Adults Without Chronic Kidney Disease
por: Itano, Seiji, et al.
Publicado: (2020)

Randomised clinical trial of ferric citrate hydrate on anaemia management in haemodialysis patients with hyperphosphataemia: ASTRIO study
por: Yokoyama, Keitaro, et al.
Publicado: (2019)

Dapagliflozin, advanced chronic kidney disease, and mortality: new insights from the DAPA-CKD trial
por: Marx, Nikolaus, et al.
Publicado: (2021)

Complete heart block in a boy with hyperostosis–hyperphosphataemia syndrome: a case report
por: Hosseini, Zahra, et al.
Publicado: (2019)

Endovascular renal denervation: a novel sympatholytic with relevance to chronic kidney disease
por: Hoye, Neil A., et al.
Publicado: (2014)

The Impact of Early-Stage Chronic Kidney Disease on Weight Loss Outcomes After Gastric Bypass
por: Pereira, João, et al.
Publicado: (2023)

Mineralocorticoid receptor blockade—a novel approach to fight hyperkalaemia in chronic kidney disease
por: Ritz, E., et al.
Publicado: (2013)

The clinical impact of plasma leptin levels in a cohort of chronic kidney disease patients
por: de Oliveira, Rodrigo Bueno, et al.
Publicado: (2013)

AA Amyloidosis in a patient with glycogen storage disorder and progressive chronic kidney disease
por: Dick, Jonathan, et al.
Publicado: (2012)

Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options
por: Jankowski, Joachim, et al.
Publicado: (2021)

Targeting Gastrointestinal Transport Proteins to Control Hyperphosphatemia in Chronic Kidney Disease
por: Fouque, Denis, et al.
Publicado: (2018)

Fasting during the month of Ramadan among patients with chronic kidney disease: renal and cardiovascular outcomes
por: NasrAllah, Mohamed M., et al.
Publicado: (2014)

Clinical and demographic predictors for vitamin D deficiency in multiethnic Asian patients with chronic kidney disease
por: Loh, Zhong Yi, et al.
Publicado: (2012)

The Impact of Chronic Kidney Disease in Patients With Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiation
por: Dudani, Shaan, et al.
Publicado: (2021)

Cardiovascular risk markers associated with arterial calcification in patients with chronic kidney disease Stages 3 and 4
por: Kiu Weber, Chek Ing, et al.
Publicado: (2014)

Etiological Subtypes of Transient Ischemic Attack and Ischemic Stroke in Chronic Kidney Disease: Population-Based Study
por: Kelly, Dearbhla M., et al.
Publicado: (2020)

Bright’s Disease of the Kidney
por: Bartlett, John
Publicado: (1864)

Vitamin D and Secondary Hyperparathyroidism in Chronic Kidney Disease: A Critical Appraisal of the Past, Present, and the Future
por: Brandenburg, Vincent, et al.
Publicado: (2022)

Efficacy and safety of PT20, an iron-based phosphate binder, for the treatment of hyperphosphataemia: a randomized, double-blind, placebo-controlled, dose-ranging, Phase IIb study in patients with haemodialysis-dependent chronic kidney disease
por: Sampson, Mark, et al.
Publicado: (2020)

Magnesium and FGF-23 are independent predictors of pulse pressure in pre-dialysis diabetic chronic kidney disease patients
por: Fragoso, André, et al.
Publicado: (2014)

Biomarkers for the prediction of acute kidney injury: a narrative review on current status and future challenges
por: de Geus, Hilde R. H., et al.
Publicado: (2012)

How good are we at managing acute kidney injury in hospital?
por: Meran, Soma, et al.
Publicado: (2014)

Does Chronic Kidney Disease Predict Stroke Risk Independent of Blood Pressure?: A Systematic Review and Meta-Regression
por: Kelly, Dearbhla M., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_u5k3pf1npvikkk7sjk1scukjlu